Contact

Redefining Neurodegeneration Therapy

Precision Medicines

for Parkinson’s Disease

On a mission to discover and develop disease-modifying treatments for genetically-driven degenerative disorders

Overcoming the Barriers to Effective
Therapies for Parkinson’s Disease

We use a multi-disciplinary approach to slow disease progression and restore neuron function.

Problem
  • Current treatments do not address the root cause of Parkinson’s Disease
  • More than 1 million people with Parkinson’s Disease in the US need better treatments, urgently
Solution
  • Optimized variants of human enzymes that overcome the subpar efficacy of the natural version

Platform

A Platform Built for Precision and Performance

Addressing root causes of neurodegeneration with AI-optimized enzymes.

Our AI-driven platform generates efficacious, CNS-delivered therapeutics for streamlined clinical development, based on a suite of proprietary technologies:

BoldSeq™

Protein Optimization

B3Bold™

CNS Delivery

GloBold™

Target Discovery

A Paradigm Shift for Parkinson’s Disease

A comprehensive engineering approach to better target neurodegeneration and discover treatments to combat it.

Built by Therapeutic Enzyme Experts

Gjalt Huisman, PhD

CEO

Victoria Wong, MSC

Head of Translational Sciences

Vesna Mitchell, PhD

Head of Molecular Biology & Research Operations

Mark Hochstetler, MBA

Head of Finance & BD

Our Pipeline

Our Pipeline

EMB-0141: a potential game-changer for GBA-PD

Mutations in the GBA1 gene, which encodes the enzyme glucocerebrosidase (GCase), cause Gaucher disease (GD) and are the most common genetic risk factor for Parkinson’s disease (PD), present in ~5—15% of PD patients.

Reduced GCase activity is observed in GBA-PD and also in idiopathic PD. Although the precise mechanism is still under investigation, a clear link exists between reduced GCase activity, α-synuclein accumulation, and PD pathology. Boosting GCase activity is a well-recognized therapeutic strategy for PD.

However, natural human GCase (hGCase) is inherently unstable, with poor serum half-life, rapid clearance, and manufacturing challenges that have limited its use beyond peripheral GD. We have overcome these limitations by creating optimized GCase variants with improved expression, stability, and delivery properties, potentially enabling safe and effective treatment for GBA-PD, iPD, and neuronopathic GD.

Contact